Andrews William T. sold (to issuer) $73K of CPRX
Andrews William T. (Chief Medical Officer) sold (to issuer) 2,309 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 on 2026-07-15.
How this was made
The 30-second read
Why it matters
The disclosure provides transaction details (shares, price, total value) but no new information about Catalyst’s pipeline, trials, approvals, or financial guidance.
Market read
Traders may note insider activity, but this specific sale does not introduce a new fundamental catalyst.
What to watch
Insider sales to the issuer can be mechanical (e.g., buyback participation) and may not reflect forward-looking views; also, the insider ends with 0 shares, limiting future signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals, Inc. (CPRX).
Ticker impact
Catalyst Pharmaceuticals CMO William T. Andrews sold 2,309 shares to the issuer at $31.50 on 2026-07-15, per Form 4.
Likely minimal near-term impact; any effect is more about signaling than fundamentals.
Form 4 shows a small, non-transactional insider sale size relative to company fundamentals, and the filing provides no new operational or regulatory catalyst.
Market effects
No clear read-across to biotech sector fundamentals from a single routine insider sale.
None.
None.
Counterpoint
The absence of a pre-arranged 10b5-1 plan could be interpreted as less routine, but the filing still lacks any accompanying company-specific catalyst.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
CPRX, the company whose insider transaction is disclosed on Form 4.
- insiderWilliam T. Andrews
Chief Medical Officer who sold shares to the issuer.